On both sides of the Atlantic pharma companies are presenting cases to the courts and to national regulators that the innovation cash pipelines will be disrupted, forcing them to either cut back and delay launches or move operations to Asia Pacific or Latin America. Find out more in our newly published whitepaper featuring industry experts: · Christoph Glaetzer, Dipl.Kfm., Chief Global Value and Access at Johnson & Johnson Innovative Medicine · Ricardo Werner Marek, President Europe & Canada at Takeda · Andy Powrie-Smith, Executive Director, Communications & Partnerships at EFPIA - European Federation of Pharmaceutical Industries and Associations Access the full whitepaper here: https://bit.ly/3Vh46Y2
Daniel Baker’s Post
More Relevant Posts
-
What makes Novartis and other top pharma companies stand out in Europe? Meet the leaders driving innovation: Vasant Narasimhan (Novartis), Bill Anderson (Bayer), Paul Hudson (Sanofi), Pascal Soriot (AstraZeneca), and many more. Discover their focus areas and global strategies. Read more here: https://ow.ly/QHtZ50SJjIe #Pharma #Healthcare #HealthcareLeaders
-
The pharmaceutical industry is evolving rapidly– but how might commercial models in pharma evolve over the next years? What does it take to build a truly innovative, and analytics-driven go-to-market model to help enable healthcare professionals driving patient impact? How might industry leaders think about transforming their commercial model? Davide Piras from Bristol Myers Squibb will join McKinsey & Company experts Jan Ascher and Nils Peters to talk about the commercial model of the future on September 26th in the first webinar of our Next Generation Pharma Commercial series, hosted by Christoph Acher and Wolfgang Trasischker. Do you want to join Davide and your peers to discuss the next generation pharma commercial model? Register today to mark your calendar: https://lnkd.in/dECz4zQh #CX #Pharma #Commercial #Digital #Webinar
-
-
Next week I will join Nils Peters and Jan Ascher from McKinsey to discuss the commercial model of the future and reflect on my experience driving a CX transformation. For more information and registration see the post below. I am looking forward to the discussion!
The pharmaceutical industry is evolving rapidly– but how might commercial models in pharma evolve over the next years? What does it take to build a truly innovative, and analytics-driven go-to-market model to help enable healthcare professionals driving patient impact? How might industry leaders think about transforming their commercial model? Davide Piras from Bristol Myers Squibb will join Jan Ascher and me to talk about the commercial model of the future on September 26th in the first webinar of our Next Generation Pharma Commercial series, hosted by Christoph A. and Wolfgang Trasischker. Do you want to join Davide and your peers to discuss the next generation pharma commercial model? Register today to mark your calendar: https://lnkd.in/dgpy2GBH #CX #Pharma #Commercial #Digital #Webinar
-
-
The pharmaceutical industry is evolving rapidly– but how might commercial models in pharma evolve over the next years? What does it take to build a truly innovative, and analytics-driven go-to-market model to help enable healthcare professionals driving patient impact? How might industry leaders think about transforming their commercial model? Davide Piras from Bristol Myers Squibb will join McKinsey & Company experts Jan Ascher and Nils Peters to talk about the commercial model of the future on September 26th in the first webinar of our Next Generation Pharma Commercial series, hosted by Christoph A. and Wolfgang Trasischker. Do you want to join Davide and your peers to discuss the next generation pharma commercial model? Register today to mark your calendar: https://lnkd.in/ddNMV2Ke #CX #Pharma #Commercial #Digital #Webinar
-
-
McKinsey, lives and livelihoods communications, leading growth and operational excellence, Board and C-suite executive
The pharmaceutical industry is evolving rapidly– but how might commercial models in pharma evolve over the next years? What does it take to build a truly innovative, and analytics-driven go-to-market model to help enable healthcare professionals driving patient impact? How might industry leaders think about transforming their commercial model? Davide Piras from Bristol Myers Squibb will join McKinsey & Company experts Jan Ascher and Nils Peters to talk about the commercial model of the future on September 26th in the first webinar of our Next Generation Pharma Commercial series, hosted by Christoph Acher and Wolfgang Trasischker. Do you want to join Davide and your peers to discuss the next generation pharma commercial model? Register today to mark your calendar: https://lnkd.in/dBMfckiD #CX #Pharma #Commercial #Digital #Webinar
-
-
💊 Samuel Hollis takes us on his two-decade journey through the pharmaceutical industry, sharing insights from his roles across the UK, Switzerland, and the US. Samuel talks about his passion for science, career progression, and the importance of innovation and leadership in pharma. This edition provides some valuable insight into the pharmaceutical industry, including what it takes for clinicians to make the switch into pharma. He also delves into his fascinating lobster theory! Make sure you give the article a read on Peerr to find out more ⬇🦞 https://lnkd.in/eQ_h_Mec
-
-
A great look into the world of pharma through the eyes of the incredible Samuel Hollis. It’s a must read for those of you who are interested in making the move into pharma, or simply want to learn more about the industry! 🗞️💊
💊 Samuel Hollis takes us on his two-decade journey through the pharmaceutical industry, sharing insights from his roles across the UK, Switzerland, and the US. Samuel talks about his passion for science, career progression, and the importance of innovation and leadership in pharma. This edition provides some valuable insight into the pharmaceutical industry, including what it takes for clinicians to make the switch into pharma. He also delves into his fascinating lobster theory! Make sure you give the article a read on Peerr to find out more ⬇🦞 https://lnkd.in/eQ_h_Mec
-
-
🗣️ A great summary of our episode with Samuel Hollis, which provides you with fascinating insight into the pharmaceutical industry. Give it a read to learn more about pharma, as well as for some insightful tips from Samuel about career development. 🚀
💊 Samuel Hollis takes us on his two-decade journey through the pharmaceutical industry, sharing insights from his roles across the UK, Switzerland, and the US. Samuel talks about his passion for science, career progression, and the importance of innovation and leadership in pharma. This edition provides some valuable insight into the pharmaceutical industry, including what it takes for clinicians to make the switch into pharma. He also delves into his fascinating lobster theory! Make sure you give the article a read on Peerr to find out more ⬇🦞 https://lnkd.in/eQ_h_Mec
-
-
Today the #BoardofDirectors of Medtech & Pharma Platform Association convened at the Novartis campus to chart the future course of action for our association. I am honored as #President to chair the #BoardofDirectors and truly inspired by the unwavering dedication and collaborative spirit demonstrated by each #member of our #Board. Together, we are committed to #fostering #synergy among the #pharmaceutical, #medtech, #diagnostic, and #tech sectors, with the aim of expanding access to vital health technologies. Your contributions are invaluable and pivotal in effecting positive change. Our association stands as a beacon of collaboration, representing #medtech, #diagnostic, #pharmaceutical, and #tech companies dedicated to advancing #combinedproducts. For those who share our passion for enhancing #cross-sectoral synergies and for improving access to health technologies, I extend an invitation to join us in our mission. Click here to learn more: https://bit.ly/3KGx1hz #Medtech #Pharma #Tech #InnovativeProducts #CombinedProducts #CombinationProducts #EuropeanUnion
Today, the Medtech & Pharma Platform Association's Board of Directors convened at the Novartis Campus to discuss the future strategy of our unique industry association, which represents medtech, diagnostic, pharmaceutical, and tech companies involved in combined products. We extend our gratitude to all Board members for their input and commitment to our mission of fostering collaboration among the pharmaceutical, medical technology, and tech sectors to advance and broaden access to combined products. Their dedication is truly making a difference! -Shayesteh Fürst-Ladani, President -Stephan A., Ypsomed AG -Daniel Delfosse, Swiss Medtech -Stephanie Horn, Roche -Manfred Maeder, Novartis -Ruth Foster, MSD -Fanny Barbotin, BD Additionally, we would like to thank the members of our Secretariat, Nathalie Schober-Ladani, Samuel Gavillet and Adrian Sutter, for their daily and unwavering support. If you are interested in joining us in our mission to improve access to combined products and enhance cross-sectoral synergies visit our website: https://bit.ly/3KGx1hz #Medtech #Pharma #Tech #InnovativeProducts #CombinedProducts #CombinationProducts #EuropeanUnion
-
-
We are proud to announce that MSD Polska has once again been awarded the prestigious status of a research and development center by the Minister of Development and Technology. This award confirms our continued commitment to: 💊 Developing innovative therapies 🔬 Conducting clinical trials in Poland 🇵🇱 Supporting Polish science and economy Key facts: - MSD Polska is one of 61 companies in the country with this status - We are among only 4 global biopharmaceutical companies with this distinction - We are currently conducting about 150 clinical trials involving about 3,700 Polish patients We are happy to support Polish science, economy and health care system. Together we are creating a healthier future! 💪 To read more: https://lnkd.in/eF2G2wh5 #MSDPolska #InnovationInHealthcare #researchanddevelopment #ClinicalTrials 🚀
